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During human cytomegalovirus (HCMV) infection, the promoters for the classical NF-kB subunits (p65 and
p105/p50) are transactivated. Previously, we demonstrated that the viral immediate-early (IE) proteins (IE1-
72, IE2-55, and IE2-86) were involved in this upregulation. These viral factors alone, however, could not
account for the entirety of the increased levels of transcription. Because one of the hallmarks of HCMV
infection is the induction of cellular transcription factors, we hypothesized that one or more of these induced
factors was also critical to the regulation of NF-kB during infection. Sp1 was one such factor that might be
involved because p65 promoter activity was upregulated by Sp1 and both of the NF-kB subunit promoters are
GC rich and contain Sp1 binding sites. Therefore, to detail the role that Sp1 plays in the regulation of NF-kB
during infection, we initially examined Sp1 levels for changes during infection. HCMV infection resulted in
increased Sp1 mRNA expression, protein levels, and DNA binding activity. Because both promoters were
transactivated by Sp1, we reasoned that the upregulation of Sp1 played a role in p65 and p105/p50 promoter
activity during infection. To address the specific role of Sp1 in p65 and p105/p50 promoter transactivation by
HCMV, we mutated both promoters. These results demonstrated that the Sp1-specific DNA binding sites were
involved in the virus-mediated transactivation. Last, to further dissect the role of HCMV in the Sp1-mediated
induction of NF-kB, we examined the role that the viral IE genes played in Sp1 regulation. The IE gene
products (IE1-72, IE2-55, and IE2-86) cooperated with Sp1 to increase promoter transactivation and physically
interacted with Sp1. In addition, the IE2-86 product increased Sp1 DNA binding by possibly freeing up inactive
Sp1. These data supported our hypothesis that Sp1 was involved in the upregulation of NF-kB during HCMV
infection through the Sp1 binding sites in the p65 and p105/p50 promoters and additionally demonstrated a
potential viral mechanism that might be responsible for the upregulation of Sp1 activity.
Human cytomegalovirus (HCMV) is rarely associated with
clinical symptoms in immunocompetent individuals. However,
in immunocompromised individuals, in transplant patients,
during pregnancy, and in certain other instances, HCMV in-
fection can manifest itself in severe and often fatal conditions
(for a review, see reference 27). During HCMV infection, an
organized cascade of events must take place in order to gen-
erate a productive infection. This cascade involves an ordered
regulation of viral genes starting with the immediate-early (IE)
genes, followed by the early genes and finally the late family of
genes (44). The viral IE gene products are the earliest family of
regulators expressed, and these gene products are essential for
the induction of the early and late gene families. The expres-
sion of these vital IE genes is predominantly, if not completely,
dependent on host cell transcription factors. This requirement
for host cell factors is hypothesized to be the reason for the
massive upregulation of cellular transcription factors following
HCMV infection.
One of these essential transcription factors induced during
HCMV infection is NF-kB. Previously, it was demonstrated
that infection results in a rapid induction of nuclear NF-kB
DNA binding activity by a receptor/ligand-mediated process
and an increase in the steady-state message levels for the two
classical NF-kB subunits, p50 and p65 (6, 38, 51, 64, 65).
Classical NF-kB, a member of the rel family of transcription
factors, is a heterodimeric complex made up of two subunits, a
50-kDa (p50, NF-kB1) protein and a 65-kDa (p65, RelA) pro-
tein (for reviews, see references 18, 52, and 57). Under non-
stimulatory conditions, NF-kB is found in the cytosol in an
inactive complex with an inhibitor termed IkB (1, 2, 18, 25, 52,
57). IkB functions by blocking the nuclear localization signal of
NF-kB, thereby preventing its mobilization to the nucleus (5,
20, 66). Stimulation results in the release of NF-kB from IkB,
mobilization to the nucleus, and subsequent activation of NF-
kB-inducible genes (18, 52, 57).
The importance of NF-kB for the virus stems from its critical
role in the regulation of the major IE promoter (MIEP) (9, 51)
and consequently the regulation of the essential HCMV IE
genes (for a review of the IE genes, see reference 55). The
MIEP and many other viral promoters have consensus NF-kB
binding sites which have been demonstrated to be critical to
their regulation (9, 21, 51). NF-kB is also utilized by other
herpesviruses and nonherpesviruses (10, 24, 49). The essential
role for NF-kB during HCMV infection is further underscored
by the fact that to date, no other stimulus has been docu-
mented to upregulate p65 message expression (38, 65). During
HCMV infection, NF-kB is modulated in two tiers. Initially,
there is a release of preformed stores within minutes of a
virus-cell interaction in a protein synthesis-independent man-
ner (6, 63–65), followed by the de novo synthesis of new prod-
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uct via p65 and p105/p50 promoter transactivation (65). The
second tier of regulation, the de novo synthesis of new NF-kB,
appears to occur by at least two important and distinct mech-
anisms and is dependent on protein synthesis (65). The first
mechanism involves the HCMV IE genes (IE1-72 or IE72,
IE2-55 or IE55, and IE2-86 or IE86 [for a review, see reference
55]) which are expressed during the time frame in which we see
NF-kB upregulation and can transactivate the p65 and p105/
p50 promoters (65). Second and equally important is the role
of cellular transcription factors in the regulation of these pro-
moters (65).
This previous study (65), although suggesting that cellular
factors were involved, did not examine in detail the nature of
their specific involvement. Thus, we next undertook a study to
examine the role that cellular factors played in the regulation
of the two primary rel family members induced during infec-
tion, p65 and p105/p50. The role that NF-kB plays in this
promoter regulation might be a logical starting point for in-
vestigation because it has been shown to autoregulate the
p105/p50 promoter (12, 56); however, because it does not
transactivate the p65 promoter (60), other cellular transcrip-
tion factors must play a critical role in the regulation of the
NF-kB subunit promoters, particularly the p65 promoter. Our
previous work implied that Sp1 might be an important player
in the regulation of the p65 promoter (65). In addition, the p65
and p105/p50 promoter regions are GC rich and contain pu-
tative Sp1 binding sites (12, 56, 60). In fact, the p65 promoter
may contain only Sp1 binding sites (60). Therefore, we chose to
focus the present study on determining whether the transcrip-
tional upregulation of p65 and p105/p50 following HCMV
infection (38, 65) might be mediated by Sp1. Sp1 is a transcrip-
tion factor that binds to specific GC-rich elements known as
GC boxes (15, 16, 22), is derived from a single gene product
(33, 50), and is heavily posttranslationally modified (7, 28, 29).
The mechanisms involved in the control of Sp1 activity remain
largely uncharacterized, although there have been several re-
cent reports describing potential regulatory products (8, 35, 41,
42, 58, 59). Like NF-kB, Sp1 is an important player in the
regulation of cellular transcription and is utilized in the regu-
lation of both herpesvirus and nonherpesvirus gene products
(17, 28, 31, 32, 50, 67). As presented in this work, an upregu-
lation of Sp1 mRNA, protein, and DNA binding occurred
during HCMV infection, the induction of both NF-kB promot-
ers (the p65 and p105/p50 promoters) was significantly upregu-
lated by Sp1, and the Sp1 sites in these promoters were shown
to be necessary for promoter transactivation during infection.
We also showed a link between the HCMV IE gene products
and Sp1 regulation, suggesting a model whereby the viral in-
duction of Sp1 plays a regulatory role in the second tier of
NF-kB regulation and thus helps maintain the cellular envi-
ronment necessary for the continuation of the viral gene cas-
cade.
MATERIALS AND METHODS
HCMV and cells. Human embryonic lung (HEL) fibroblasts were cultured in
Eagle’s minimal essential medium supplemented with 10% fetal bovine serum
(GIBCO BRL, Gaithersburg, Md.) at 37°C in a 5% CO2 incubator prior to use.
HCMV Towne strain was passaged as previously described (26). For all exper-
iments in which HEL fibroblasts were infected, a multiplicity of infection (MOI)
of 2 to 3 was used. Cells and virus were incubated for 90 min at 37°C in a 5% CO2
incubator, and the free virus was then washed off (we have termed this time zero
[t0]), and the cells were cultured for the desired length of time in Eagle’s minimal
essential medium supplemented with heat-inactivated 4% fetal bovine serum
(GIBCO BRL) at 37°C in a 5% CO2 incubator. The cells were harvested at the
times stated in Results. For experiments involving the Sp1-negative Drosophila
Schneider line 2 (SL2) cells, cells were cultured in Schneider’s Drosophila me-
dium (GIBCO BRL) supplemented with 12% fetal bovine serum (GIBCO BRL)
at room temperature with continuous stirring as described previously until
needed (65). Cells were then plated at 5 3 106, incubated overnight, and used for
transfections as stated below.
GST Fusion protein purification. The glutathione S-transferase (GST) fusion
proteins were collected and harvested as stated previously (19). Briefly, GST
fusion proteins were purified from bacterial lysates and bound to glutathione-
Sepharose 4B beads (Pharmacia Biotech, Piscataway, N.J.). For the GST-IE
fusion proteins, the beads were washed five times with an ice-cold 1% Triton
X-100 (Sigma, St. Louis, Mo.)–phosphate-buffered saline solution. The GST
fusion proteins were then eluted with a 20 mM reduced glutathione (Boehringer
Mannheim Corporation, Indianapolis, Ind.)–100 mM Tris-HCl (pH 8.0) solu-
tion, dialyzed, and stored at 270°C until needed. The construction and charac-
terization of the GST–IE1-72, GST–IE2–55, and GST–IE2-86 products, as well
as the GST alone were described previously (19). The GST-Sp1 used in these
experiments was attached to the glutathione-Sepharose 4B beads (Pharmacia)
and then used immediately for investigation of protein-protein interactions. The
GST-Sp1 fusion protein was a generous gift from T. D. Gilmore (54).
Nuclear extract isolation. Briefly (14, 38, 65), an infection time course of HEL
fibroblasts was collected and then incubated for 4 min on ice with a cytoplasmic
isolation buffer (10 mM HEPES [pH 7.6], 60 mM KCl, 1 mM EDTA, 0.1%
Nonidet P-40 [NP-40], 1 mM dithiothreitol [DTT], 1 mM phenylmethylsulfonyl
fluoride [PMSF; Sigma], 2 mM phenanthroline [Sigma], 250 mM dichloroisocou-
marin [Sigma], 100 mM E-64 [Sigma], 10 mM pepstatin A [Sigma]). The cyto-
plasmic samples were collected by centrifugation and removal of the cytoplasmic
supernatant. The nuclear extract was then isolated by washing the remaining
pellet with the above-mentioned cytoplasmic buffer (without NP-40) and then
incubating the sample for 10 min on ice with the nuclear isolation buffer (20 mM
Tris [pH 8.0], 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM PMSF,
25% glycerol, 2 mM phenanthroline, 250 mM dichloroisocoumarin, 100 mM
E-64, 10 mM pepstatin A). These extracts were spun, and the supernatant was
collected and then stored at 270°C.
RNA isolation and Northern blot analysis. Total cellular RNA was harvested
from infected HEL fibroblasts at various times, mock through 96 h postinfection
(hpi), in a 4 M guanidine isothiocyanate solution and isolated by cesium chloride
equilibrium centrifugation. Equal cell number of total cellular RNA was elec-
trophoresed on a 1% denaturing formaldehyde agarose gel and transferred to a
nitrocellulose membrane (Immobilon-NC; Millipore, Bedford, Mass.). The
Northern blot analysis was repeated three times, and the data presented are from
a representative experiment. The blots were incubated overnight at 42°C with a
nick-translated (Boehringer Mannheim), Sephadex column (Boehringer Mann-
heim)-purified, [a-32P]dATP (ICN, Irvine, Calif.)-labeled 2.1-kb cDNA se-
quence specific for Sp1 (an XhoI fragment digested from the pPacSp1 expression
plasmid [13]). The blots were washed to a stringency of 0.23 SSC (13 SSC is 0.15
M NaCl plus 0.015 M sodium citrate) at 56°C, developed, and examined by
autoradiography.
Western blot analysis. Lysate for Western blot analysis was collected and
harvested in two different ways: (i) whole-cell lysate from a time course of
infected HEL fibroblasts was harvested in a sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) sample buffer, scraped, boiled, and
then stored at 220°C; or (ii) cytoplasmic and nuclear extracts as described above
were mixed 1:2 in an SDS-PAGE buffer, boiled, and then stored at 220°C.
Samples were electrophoresed on an SDS–6% polyacrylamide gel, and then the
proteins were transferred overnight to nitrocellulose (Immobilon-P; Millipore).
Protein concentrations were determined, and equal protein amounts were added
to each lane. The blots were blocked with a 5% skim milk–0.1% Tween 20
solution for 1 h and incubated with the primary antibody (1:2,000 anti-human
Sp1; Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) for 1 h. Next, the blots
were washed three times, incubated with the secondary antibody for 1 h (Sigma),
washed three times, incubated with the developing agent, and developed accord-
ing to the enhanced chemiluminescence protocol (Amersham Life Sciences,
Arlington Heights, Ill.).
EMSAs. Nuclear extracts were incubated for 15 min in a binding buffer (10
mM Tris-HCl, 50 mM NaCl, 0.5 mM EDTA, 10% glycerol, 1 mM DTT) plus 7.5
mM MgCl2, 0.1 mg of poly(dI-dC) (Pharmacia Biotech), and a 32P-labeled wild-
type GC box (59-CCTTTTTAAGGGGCGGGGCTT-39) or a mutant GC box (59-
CCTTTTTAAGGTTCGGGGCTT-39) double-stranded oligonucleotide probe for
the experiments examining Sp1 DNA binding (3, 65). The samples were electro-
phoresed on a 5% polyacrylamide gel, dried, and developed with intensifier
screens at 270°C. For the electrophoretic mobility shift assays (EMSAs) in which
the GST fusion proteins were added, equal protein amounts of the different
fusion proteins and GST alone were incubated with the above-mentioned prod-
ucts for the same length of time. Titrations of the fusion products and different
incubation conditions were done to determine the optimal conditions for these
experiments (data not shown). The oligonucleotide probes containing T over-
hangs and C ends were labeled by filling in the recessed 39 ends with
[a-32P]dATP (ICN) by using Klenow enzyme (Boehringer Mannheim), chased
with unlabeled dATP and dGTP, and then finally Sephadex (Boehringer Mann-
heim) column purified. An anti-Sp1 antibody (Santa Cruz Biotechnology) with or
without the appropriate blocking peptide (Santa Cruz Biotechnology) was used
to supershift the specific complexes of interest by pretreating the extracts for 15
min at 4°C with antibody or antibody plus peptide (preincubated overnight at 4°C
as specified by the supplier).
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Transfection and CAT assays. For the transfection-infection experiments, 10
mg of plasmid DNA (full-length and mutant promoter constructs) was trans-
fected into HEL fibroblasts by the calcium phosphate procedure and incubated
overnight (65). The cells were then washed twice in phosphate-buffered saline
and either (i) infected at an MOI of 2 to 3 and incubated for an additional 48 h
or (ii) incubated for an additional 48 h without virus and treated as mock-
infected cells. For cotransfection experiments, 10 mg of promoter chloramphen-
icol acetyltransferase (CAT) construct (full length or mutant) was cotransfected
along with 10 mg of either the Sp1 expression plasmid, pPacSp1 (13), or the
negative control Sp1 frameshift mutant, pFXSp1 (67), and then incubated for
48 h. In addition, in some experiments 10 mg of DNA from each of the HCMV
IE constructs (pcDNA3-IE1-72, -IE2-55, and -IE2-86 [65]) was cotransfected
along with the pPacSp1 or pFXSp1 construct. Titrations of the various expression
plasmids were done to determine a dose-response curve (data not shown). In all
transfection experiments, equal amounts of DNA were always added to all plates
of cells. After incubation, cells were harvested and assayed for CAT activity.
CAT activity was normalized by using equal protein amounts per sample, as well
as assaying for b-galactosidase activity as a means to equalize for transfection
efficiency. Levels of activity were analyzed by counting the [14C]chloramphenicol
(Dupont NEN, Boston, Mass.) in acetylated forms and comparing these results
to those for the unacetylated forms. The full-length CAT constructs used in this
investigation, pKBCAT (the p65 promoter [60, 65] and pHSCAT (the p105/p50
promoter [12, 65]), were described before. The backbone vectors alone (pCAT
Basic [Promega, Madison, Wis.] and pUCCAT [12]) were used as a negative
control. Additionally, 59-39 deletion constructs and site-directed mutants were
made. For construction of the p65 promoter deletion constructs (p65F1CAT,
p65F3CAT, p65F5CAT, and p65F6CAT [this construct also contains a site-
directed mutation in the last GC box]), PCR primer pairs were determined from
the p65 promoter sequence (60) and then used to make the different mutants.
For the construction of the p65-site-directed mutant (p65F1DDCAT), mutated
nested primer pairs were constructed (mutations were made in the specific
GC-box sequences) and used to make this construct. These constructs were then
purified and ligated by using a T4 DNA ligase (GIBCO BRL) to a linearized
pCAT Basic (Promega). See Fig. 4E for schematic diagrams of the constructs.
The p105/p50 promoter deletion constructs were made by enzymatic digestion of
the full-length promoter (pSpSCAT, SphI; pHiSCAT, HinfI; pASCAT, ApoI)
followed by purification and ligation to linearized pUCCAT (12). The p105/p50-
site-directed mutant (pHSLUCDSp1) was made and luciferase activity was de-
termined as previously described (11). See Fig. 5E for diagrams of the constructs.
In addition to the controls stated above, Western blot analyses were performed
on harvested lysates from the cotransfected cells to confirm equal expression of
Sp1 or for expression of the IE gene products.
In vitro interactions. Transcription-translation of the HCMV IE proteins
(IE1-72, IE2-55, and IE2-86) was done by using the Promega TnT coupled
reticulocyte lysate system for [35S]methionine labeling (Promega) as specified by
the manufacturer. The purity of the products was examined prior to use on an
SDS–10% polyacrylamide gel and subsequently visualized by autoradiography.
For examination of the in vitro interactions, Sepharose 4B beads (Pharmacia)
complexed with GST-Sp1 were washed three times with ELB1 buffer (0.25 M
NaCl, 0.1% NP-40, 0.05 M HEPES [pH 7.0], 0.001 M PMSF, 0.005 M EDTA, 0.5
mM DTT) and then incubated with the in vitro-translated IE products for 1 h at
4°C. The complexes were washed five times with ELB1 buffer and boiled in
Laemmli sample buffer. Proteins were then resolved by electrophoresis through
a SDS–10% polyacrylamide gel and visualized by autoradiography.
RESULTS
Sp1 message and protein levels were increased in HEL fi-
broblasts following HCMV infection. Our previous data sug-
gested that in addition to the role of the viral IE products,
virally induced host cell factors, such as Sp1, also provided an
important contribution to the activation of the NF-kB promot-
ers (65). Therefore, to further our study on the regulation of
the NF-kB promoters, we first addressed whether Sp1 levels
were altered during infection and thus could be a cellular
candidate for the induction of the p65 and p105/p50 promoters
during HCMV infection. A time course of whole-cell RNA
from mock through 96 hpi was examined by Northern blot
analysis. From Fig. 1A, it can be seen that there was an in-
crease in the 8.2-kb Sp1 message (33, 50) by as early as what we
have previously termed t0 (90 min after virus addition, the viral
absorption stage), and this increase continued until late times
of infection. The two- to threefold increase that was seen in
Sp1 message levels at t0 parallels the early increase seen in
p105/p50 message levels (65). Maximum steady-state levels of
Sp1 mRNA were detected at 24 to 72 hpi, with a 10-fold
increase in message levels by 48 hpi. Next, changes in Sp1
protein levels after HCMV infection were analyzed. Whole-
cell and nuclear lysates were isolated and then examined by
Western blot analysis with an anti-Sp1 monoclonal antibody
(Fig. 1B). These results demonstrated that Sp1 protein levels
increased following infection in a biphasic pattern, with an
early peak at t0 to 4 hpi and then a second peak beginning at
24 hpi. The increase in Sp1 protein levels reached a maximum
of 10- to 20-fold at 48 hpi. The changes in Sp1 protein levels in
the whole-cell lysates paralleled the changes seen in the nu-
clear lysates, the exception being at 96 hpi, when a significant
decrease in Sp1 nuclear levels was detected. This apparent
discrepancy can be explained by the results of Western blot
analysis of cytosolic extracts collected from cells at these late
times of infection. Significant amounts of Sp1 was found in the
cytosolic extracts at late times after infection (48 to 96 hpi [data
not shown]). In both whole-cell and nuclear lysates, beginning
at 24 hpi (and beyond) and to a lesser extent at the t0 to 4-hpi
peak, equal amounts of the slower (phosphorylated)- and
faster (unphosphorylated)-migrating species of Sp1 were seen
compared to the other time points.
HCMV infection also upregulates Sp1 DNA binding activity.
To investigate whether HCMV-mediated upregulation of Sp1
resulted in elevated Sp1 DNA binding activity, EMSAs were
performed. The results of the Sp1 DNA binding activity pre-
sented in this report (Fig. 2) are from an expanded time course
using the same conditions as were used for Fig. 1. A biphasic
increase in Sp1 DNA binding following infection was seen,
with one peak at 4 hpi (lane 3; a $5-fold increase in activity)
and a second peak beginning at 24 hpi (lanes 6 to 10; a 5- to
20-fold increase, depending on the time point) that remained
elevated throughout the course of infection. There was a slight
decrease in DNA binding detected at late times of infection
(lane 10; 96 hpi) supporting the results of the Western blot
analysis (Fig. 1B). This correlation is not surprising, as all of
the lysates prepared were investigated both for protein levels
by Western blot analysis and for DNA binding by EMSA. The
extracts were also tested for the ability to bind to a mutant
probe (lane 11) and to be supershifted by anti-Sp1 antibodies
(lanes 12 and 13) to confirm the specificity of the bound prod-
ucts. As shown in Fig. 2, lane 11, there was no detectable
binding of the 48 hpi extract to a mutant GC-box probe. The
results were similar for all time points tested (data not shown).
Last, as seen in Fig. 2, lane 12, the majority of the shifted
FIG. 1. HCMV infection results in the upregulation of the message and
protein for the transcription factor Sp1. A time course of HCMV infection (MOI
of 2 to 3) of HEL fibroblasts was performed. (A) A Northern blot probed with
a nick-translated 32P-labeled cDNA probe specific for Sp1. As a control, the 28S
ribosome for each lane is shown. (B) Western blot analysis of whole-cell (W) and
nuclear (N) lysates. An anti-Sp1 antibody (Santa Cruz Biotechnology) was used
to probe the blots. The two species of Sp1 are marked on the right, and the
appropriate molecular weight marker is indicated on the left. Lanes: Mock,
uninfected cells; T09, cells harvested immediately following a 90-min viral ab-
sorption stage. The other lanes represent the time the cells were harvested after
t0. The assays were repeated, and results of a representative experiment is shown.
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complex is bona fide Sp1, as shown by the supershifted com-
plex in the presence of the anti-Sp1 antibodies. The appropri-
ate blocking peptide confirmed the specificity of the anti-Sp1
antibody used (compare lanes 12 and 13). Again, the results of
the supershift experiments were similar for all time points
tested (data not shown). The identity of the minor GC-box
binding protein(s) (also induced during infection) is unknown
and could represent other Sp family members (23, 36).
Sp1 strongly transactivates the p65 and p105/p50 promot-
ers. The work described above demonstrated that HCMV in-
fection significantly increased Sp1 levels. It did not, however,
demonstrate that the increase in Sp1 was directly related to the
increase in p65 or p105/p50 promoter activity that we have
seen (65), even though the GC-rich nature of both promoters
(12, 56, 60), the lack of other identifiable transcription factor
binding sites besides Sp1 in the p65 promoter (60), and the lack
of p65 promoter responsiveness to NF-kB (60), suggesting the
involvement of other factors such as Sp1, might indicate a link
between the two. Therefore, to directly demonstrate that a link
exists between Sp1 and p65 and p105/p50 promoter activity,
the full-length p65 and p105/p50 promoter-CAT constructs
(pKBCAT and pHSCAT, respectively) were cotransfected into
Drosophila SL2 cells (which lack endogenous Sp1) along with
either an Sp1 expression plasmid, pPacSp1 (13), or an Sp1
frameshift mutant, pFXSp1 (67). These experiments demon-
strated that Sp1 was capable of strongly transactivating both
promoters (Fig. 3A). There was a 40-fold induction of the p65
promoter (pKBCAT) and over a 30-fold induction of the p105/
p50 promoter (pHSCAT) when Sp1 was present (pPacSp1);
however, little or no CAT activity was observed in the presence
of the Sp1 frameshift control (pFXSp1). A titration of the Sp1
expression plasmid along with the frameshift mutant was also
performed and showed that as the levels of Sp1 increased, the
activities of the p65 and p105/p50 promoters (Fig. 3B and C,
respectively) also increased. Western blot analysis of the har-
vested lysate confirmed the presence of the Sp1 protein in the
extracts. These results thus demonstrated that these two
NF-kB promoters were highly responsive to Sp1 in a dose-
dependent manner.
Sp1 binding sites influence the regulation of the NF-kB
promoters. To demonstrate whether Sp1 plays a direct role in
the p65 and p105/p50 promoter regulation during infection,
59-39 deletion constructs and site-directed mutants were made
for both promoters as stated in Materials and Methods. These
promoter mutants were investigated for activity in both co-
transfection experiments (with or without Sp1) using Drosoph-
ila SL2 cells and transfection-infection experiments using HEL
fibroblasts.
(i) The p65 promoter. Because of the sole reported presence
of putative Sp1 sites in the p65 promoter (60), Sp1 responsive-
ness of the p65 promoter was investigated first via cotransfec-
tion of SL2 cells (Fig. 4A) and then via transfection-infection
of HEL fibroblasts (Fig. 4B) with the full-length p65 promoter
and various promoter deletion constructs. These results dem-
onstrated a clear role for Sp1 in the regulation of this pro-
moter. As shown in Fig. 4A, the ability of cotransfected Sp1 to
positively transactivate the p65 promoter mapped to the GC-
rich regions which contained the Sp1 DNA binding sites (Fig.
4E). Although other potential Sp1 binding motifs reside within
the p65 promoter region, the centrally located site (2232 bp)
conferred the majority of the Sp1 responsiveness, as there was
an 86% reduction in the ability of Sp1 to positively modulate
the p65 promoter when this site was deleted (Figure 4A; com-
pare p65F3CAT and p65F5CAT). In contrast to the cotrans-
fection experiments, most of the virally mediated activity was
located between 2575 and 2178, suggesting that both the
furthest 59 Sp1 site and the centrally located site were involved
in the induction of the reporter construct during infection. In
both the cotransfection experiments and the transfection-in-
fection experiments, little activity resided in the third Sp1 site
(proximal to the start site), as a construct in which a site-
directed mutation was generated in this third GC box
(p65F6CAT) had no significant difference in activity compared
to the unmutated construct (p65F5CAT). In addition, a site-
directed mutant construct in which both the 2377 bp and the
2232 bp Sp1 sites were mutated (p65F1DDCAT) was made to
specifically examine the role of the important Sp1 sites that
were documented to be responsible for activity in Fig. 4A and
B. As shown in Fig. 4C and D, there was a significant decrease
in promoter activity when the first two documented GC boxes
were mutated (p65F1DDCAT) compared to the full-length
promoter (pKBCAT) or the construct in which the GC boxes
were unaltered (p65F1CAT). There was over a 60% decrease
in activity when the point mutant construct was examined in
cotransfection experiments in SL2 cells following the addition
of pPacSp1 (Fig. 4C) and nearly a 90% decrease in activity
during HCMV infection (Fig. 4D). There was a detected low
level of activity in the p65F5CAT and p65F6CAT constructs
following viral infection. These regions, however, failed to re-
spond to Sp1-mediated transactivation, suggesting that the low
level of promoter activity observed during the transfection-
infection studies was not a result of virally induced Sp1 but
rather was a result of another factor(s) interacting through a
region near the start of transcription or the result of nonspe-
cific viral transactivation which is commonly observed in
HCMV-infected cells.
(ii) The p105/p50 promoter. In classic NF- 6 KB, one of the
predominant rel family complexes induced during HCMV in-
fection (65), p65 never functions without its cognate counter-
part p50; thus, it is equally important to examine the role of
Sp1 in the regulation of the p105/p50 promoter. Therefore, the
potential role of Sp1 in the p105/p50 promoter was also inves-
tigated by promoter mutation analysis in cotransfection (Fig.
FIG. 2. HCMV infection results in the upregulation of Sp1 DNA binding
activity in a biphasic pattern. Shown is EMSA of a time course of Sp1 DNA
binding activity during HCMV infection of HEL fibroblasts. Lanes: Mock, un-
infected cells; T09, the 90-min viral absorption step; 3 to 10, the times the cells
were harvested after t0; 11, binding to a mutant probe; 12 and 13, the supershift
and the appropriate blocking peptide (Pep) control lanes. Binding of the HEL
nuclear extracts to a wild-type (WT) consensus GC box (59-CCTTTTTAAGGG
GCGGGGCTT-39) (lanes 1 to 10, 12, and 13) or a mutant (MUT) GC box
(59-CCTTTTTAAGGTTCGGGGCTT-39) (lane 11) is shown. The specific Sp1,
supershifted Sp1 (*Sp1), and nonspecific (NS) binding activities are marked.
Competition experiments also confirmed that the activity was bona fide GC box
binding (data not shown). The data shown are from a representative experiment.
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5A and C) and transfection-infection (Fig. 5B and D) experi-
ments. As shown in Fig. 5A, p105/p50 promoter activity cor-
related with the loss of the Sp1-responsive elements. There was
nearly a 10-fold decrease in pASCAT activity compared to that
of the full-length pHSCAT reporter. When the pHiSCAT con-
struct (deletion of the NF-kB, PEA2, and AP1 sites) was used
in cotransfection experiments, there was a 58% decrease in
Sp1-mediated p105/p50 transactivation compared to the activ-
ity of the pSpSCAT construct. Because there are no Sp1 sites
in this region, the decrease was most likely not due to a loss of
direct Sp1-DNA interaction but probably due to a loss of an
interaction between Sp1 and NF-kB that has previously been
shown to promote transactivation (41, 46, 47, 53, 54). There
was also over a 50% decrease in activity when the Sp1 site in
the pHiSCAT construct was deleted (Fig. 5A; compare pHiS-
CAT and pASCAT). Like the cotransfection experiments, the
transfection-infection studies displayed a decrease in p105/p50
promoter activity when pASCAT activity was compared to the
activity of full-length pHSCAT construct. A decrease in activity
was also seen when the NF-kB sites were deleted (pSpSCAT
compared with pHiSCAT activity). The presence of activity in
the minimal pASCAT construct following infection was similar
to the results obtained for the minimal p65 construct,
p65F6CAT, further confirming our hypothesis that viral infec-
tion heightened overall transcription. There was not a signifi-
cant difference between the activities in the pASCAT and
pHiSCAT constructs during infection; however, when a con-
struct in which a documented Sp1 site in this region was mu-
tated by site-directed mutagenesis (pHSLUCDSp1 [11]) was
used, there was detected a significant decrease in activity in
both the cotransfection (66% decrease) and transfection-infec-
tion (51% decrease) experiments compared to the full-length
promoter (pHSLUC). Together, these studies demonstrate
that the cellular transcription factor Sp1 plays an important
role in the transactivation of both the p65 and p105/p50 pro-
moters and that one of the physiological results of the elevated
Sp1 levels during HCMV infection is the transcriptional up-
regulation of the NF-kB-encoding genes.
The IE gene products (IE1-72, IE2-55, and IE2-86) cooper-
ated with Sp1 to upregulate promoter activity. Previously, it
FIG. 3. The p65 and p105/p50 promoters are upregulated by Sp1. CAT assays were performed on harvested Drosophila SL2 cells that were transfected with the
various constructs or combination of constructs listed. Equal amounts of total plasmid DNA were used for all samples. (A) Comparison of the effects of Sp1 on the
p65 and p105/p50 promoters. (B) Effect of the titration of the Sp1 expression construct along with the control mutant construct on the p65 promoter. (C) Effects of
the titration of the Sp1 expression construct and the control mutant construct on the p105/p50 promoter. The constructs used are defined as follows: None, no DNA;
pKBCAT, the p65 promoter; pCAT Basic, the vector-alone control for the p65-promoter; pHSCAT, the p105/p50 promoter; pUCCAT, the vector-alone control for
the p105/p50 promoter; pPacSp1, an Sp1 expression plasmid; and pFXSp1, a frameshift Sp1 mutant. Fold induction represents the difference between the percent
acetylation of the test samples and that of the vector-alone controls. The data shown are from a minimum of three replicate experiments.
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was shown that the HCMV IE gene products significantly
transactivated the p65 promoter and to a lesser extent trans-
activated the p105/p50 promoter (64). Therefore, in an attempt
to correlate our previously reported findings involving the reg-
ulation of the NF-kB subunit promoters by the IE gene prod-
ucts to the findings in the present work, on the role of Sp1 in
the regulation of the NF-kB subunit promoters, we next ex-
amined whether the IE gene products could interact with Sp1
to promote increased levels of promoter transactivation. The
data presented in Fig. 6A show that there was nearly a 40-fold
increase p65 promoter activity (pKBCAT) following the addi-
tion of the Sp1 expression construct (pPacSp1) and that when
the IE expression plasmids (pcDNA3-IE1-72, -IE2-55, and
-IE2-86 [65]) were cotransfected along with Sp1, there was a
further increase in activity (33, 200, and 100% increases fol-
lowing the addition of IE1-72, IE2-55, and IE2-86, respective-
ly). There was little or no activity seen when the IE expression
constructs were used in the absence of functional Sp1 (either
FIG. 4. Mutational analysis of the p65 promoter. Cotransfection and transfection-infection experiments using Drosophila SL2 cells and HEL fibroblasts were
performed. (A) Drosophila SL2 cells were transfected with the various constructs listed plus or minus a functional Sp1 expression plasmid, and then CAT assays were
performed. (B) CAT assays were performed on HEL fibroblasts transfected with the constructs listed and then either infected with HCMV (MOI of 2; Virus) or mock
treated (No Virus). (C) Drosophila SL2 cells were transfected with the various constructs listed plus or minus a functional Sp1 expression plasmid. (D) HEL fibroblasts
were transfected with the constructs listed and then either infected with HCMV or mock treated. (E) Diagrams of the p65 promoter and the various mutant constructs,
with the known transcription factor binding sites indicated. The constructs used are defined as follows: pCAT Basic, vector alone; pKBCAT, the full-length
p65-promoter; p65F1CAT, p65F3CAT, and p65F5CAT, 59-39 deletion constructs of the p65 promoter; p65F6CAT, a 59-39 deletion construct of the p65 promoter with
the third Sp1 binding site mutated by site-directed mutagenesis; p65F1DDCAT, a construct in which the first two Sp1 sites were mutated by site-directed mutagenesis;
pPacSp1, an Sp1 expression plasmid; and pFXSp1, a frameshift Sp1 mutant. Fold induction represents the difference between the percent acetylation of the test samples
and that of the vector-alone controls. The data shown are from a minimum of three replicate experiments.
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no Sp1 added or the addition of the mutant control expression
construct, pFXSp1). In addition there was no activity when the
control reporter construct (pCAT Basic) or the empty vector
(pcDNA3) was used (data not shown). Similar results, al-
though less striking, were seen when the p105/p50 promoter
construct (pHSCAT) was used (data not shown), supporting
our previous findings that the IE constructs appear to play a
larger role in the upregulation of the p65 promoter than the
p105/p50 promoter and that the IE2-55 gene product is a bona
fide transactivator of this promoter (65).
IE86 increases Sp1 DNA binding activity. Because the doc-
umented increase in Sp1 DNA binding activity during infection
may not be solely the result of increased levels of Sp1 but also
the result of the release of Sp1 bound to an inhibitor as was
suggested by Chen et al. (8), we wanted to examine if an
interaction between the various IE proteins and Sp1 occurs
and to determine if the IE products could function similarly to
pRB by freeing up inactive Sp1 and thus promoting increased
Sp1 DNA binding. To perform these experiments, GST-IE
fusion proteins were added to the EMSA reaction buffer along
FIG. 5. Mutational analysis of the p105/p50 promoter. Cotransfections and transfection-infections of Drosophila SL2 cells and HEL fibroblasts were performed, and
then the harvested lysates were examined for CAT activity. (A) Drosophila SL2 cells were cotransfected with the various constructs plus or minus a functional Sp1
expression plasmid (pPacSp1 or pFXSp1). (B) HEL fibroblasts were transfected with the various constructs and then either infected with HCMV (Virus) or mock
treated (No Virus). (C) Drosophila SL2 cells were cotransfected with the various constructs plus or minus a functional Sp1 expression plasmid. (D) HEL fibroblasts
were transfected with the various constructs and then either infected with HCMV or mock treated. (E) Diagram of the p105/p50 promoter, with the binding sites for
various transcription factors indicated. The constructs used are defined as follows: pUCCAT, vector alone; pHSCAT, the full-length p105/p50 promoter; pSpSCAT,
pHiSCAT, and pASCAT, 59-39 deletion constructs of the p105/p50 promoter; pHSLUCDSp1, a full-length p105/p50 promoter in which a known Sp1 site was mutated
by site-directed mutagenesis; pHSLUC, the full-length p105/p50 promoter; pPacSp1, a Sp1 expression plasmid; and pFXSp1, a frameshift Sp1 mutant. Fold induction
represents the difference between the percent acetylation of the test samples and that of the vector alone controls. The data shown are from a minimum of three
replicate experiments.
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with the nuclear extract, prior to electrophoresis. The data
demonstrated (Fig. 6B) that the addition of GST–IE2-86 in-
creased Sp1 DNA binding in both mock and 4-hpi lysates (5- to
10-fold). GST–IE2-55 slightly increased Sp1 binding in a re-
producible manner in the 4-hpi lysate (twofold), while GST–
IE1-72 and GST alone could not, suggesting that one of the
mechanisms involved in the increased Sp1 activity seen during
infection could be mediated by the IE2-86 gene product. Ad-
ditional studies showed that this IE2-86-mediated event was
titratable and could occur at all time points tested (data not
shown). This idea of a negative regulator of Sp1 function that
mediates its effect through a direct protein-protein interaction
(8) was supported by experiments in which an increase in Sp1
DNA binding occurred following treatment of extracts with
deoxycholate to disrupt protein-protein interactions (in a man-
ner similar to that used for the disruption of the cytosolic
NF-kB–IkB complex) (63).
Sp1 physically interacts with the HCMV IE gene products.
The data presented in Fig. 6A and B suggested that there
might, in fact, be a protein-protein interaction between the IE
genes and Sp1; therefore, we examined if the IE gene products
could directly interact with Sp1. To address this possibility,
GST-Sp1 or the control product, GST alone, was incubated
with in vitro-translated IE1-72, IE2-55, and IE2-86 prior to the
GST pull-down assay and electrophoresis. The results of these
pull-down assays (Fig. 6D) demonstrated that the three IE
gene products interacted with GST-Sp1 but not GST alone.
Figure 6C shows the input level of the in vitro-translated prod-
ucts that were used in the pull-down assays presented in Fig.
6D.
DISCUSSION
In conclusion, we have demonstrated an induction of the
cellular transcription factor Sp1 during infection and showed
that Sp1 is a key player in the upregulation of the p65 and
p105/p50 NF-kB promoters. The discovery of the transactiva-
tion of the p65 and p105/p50 promoters by Sp1 supports our
hypothesis of the importance of this factor in NF-kB regulation
during HCMV infection. From a cellular and viral standpoint,
this finding has important biological consequences because
under normal circumstances, Sp1 levels are limiting within the
cell (50). If Sp1 levels are usually limiting, then overexpression
of Sp1 (such as during HCMV infection) would be expected to
dramatically increase transactivation due to the presence of the
excess pool of Sp1. Furthermore, because overexpression of
Sp1 results in superactivation (13, 45), the HCMV-induced
overexpression of Sp1 would definitely significantly affect pro-
moter regulation. With the exception of an increase in Sp1 by
simian virus 40 (28, 50), little evidence exists documenting an
increase in Sp1 levels during other types of stimulation. This
apparent viral restriction on the induction of Sp1 suggests that
it must play an essential role during the viral life cycle (at least
during simian virus 40 and HCMV infections). This potentially
vital role of Sp1 for HCMV is emphasized by our recent studies
demonstrating that the addition of Sp1 results in a 5- to 10-fold
increase in MIEP activity (63). The importance of Sp1 is fur-
ther underscored by the possibility that the p65 promoter,
which has not been documented to be induced under any
stimulus except HCMV infection (38, 65), contains only Sp1
binding sites (60).
Because of the potential importance of Sp1 in the regulation
of the NF-kB-promoters, we first investigated the regulation of
Sp1 itself during HCMV infection. There was an increase in
Sp1 mRNA expression, protein levels, and nuclear DNA bind-
ing activity ($10-fold increase in each). The increase in protein
levels and DNA binding activity followed a biphasic induction
pattern whereas the increase in message expression did not,
suggesting different mechanisms of regulation at the transcrip-
tional (and/or perhaps mechanisms of message stability) and
FIG. 6. Role of the HCMV IE gene products in the regulation of Sp1. (A)
CAT assays were performed on Drosophila SL2 cells cotransfected with the p65
promoter (pKBCAT) or the control construct (pCAT Basic) along with the Sp1
expression construct (pPacSp1) or the control construct (pFXSp1) and/or the IE
expression constructs (pcDNA3-IE1-72, pcDNA3-IE2-55, pcDNA3-IE2-86 [la-
beled IE1-72, IE2-55, IE2-86, respectively]). Equal amounts of total plasmid
DNA was used for all samples. Fold induction represents the difference between
the percent acetylation of the test samples and that of the control samples. (B)
EMSA of HEL nuclear extract pretreated with the various GST-IE fusion pro-
teins prior to electrophoresis. The specific Sp1 and nonspecific (NS) bands are
marked. A wild-type consensus GC box (CCTTTTTAAGGGGCGGGGCTT)
was used as a probe. (C) Input levels of the three in vitro-translated IE gene
products (IE1-72, IE2-55, and IE2-86) used for panel D. (D) Examination of the
interaction between Sp1 (GST-Sp1 or the control product, GST alone) and the
IE gene products (in vitro-translated IE1-72, IE2-55, and IE2-86). All experi-
ments were repeated.
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translational levels. The IE induction of Sp1 levels is probably
due to a signal transduction event that occurs following the
initial virus-ligand interaction or a virion-associated factor (64,
65), while the later peak is probably due to a combination of
viral and cellular transactivators (65). Analysis of the Western
blot data demonstrated an increase in the slower-migrating
band or the phosphorylated protein (28) at the peak times of
Sp1 induction, suggesting a change in the posttranslational
modification of this product. This finding has important ram-
ifications because Sp1 is phosphorylated only after binding to
DNA (by a DNA-dependent protein kinase [28]), suggesting
that during these peaks of Sp1 protein levels, there are also
increased levels of functionally active Sp1 binding to DNA.
This possibility is supported by recent findings that showed that
there was an increase in functional Sp1 during infection as
measured by increased Sp1-driven promoter activity in a pro-
moter construct driven solely by Sp1-responsive elements (63).
Because the goal of our study was to correlate changes in
Sp1 to the upregulation of the NF-kB subunit promoters, we
next addressed whether the p65 promoter was responsive to
Sp1. The data demonstrated that the p65 promoter strongly
responded to Sp1 and that as the levels of Sp1 increased, there
was a correlative increase in promoter activity, suggesting that
as Sp1 levels rise during infection, as we have documented,
there is probably a concomitant increase in p65 promoter ac-
tivity. To more precisely map the role of Sp1 in NF-kB pro-
moter regulation, we made a series of promoter mutants and
examined their activities in response to Sp1 alone (cotransfec-
tions in SL2 cells, which lack endogenous Sp1) and to HCMV
(transfection-infection in HEL fibroblasts) and showed that as
the Sp1 binding sites were eliminated or mutated, p65 pro-
moter activity was significantly reduced. Thus, these results
demonstrated that the GC-box elements within the p65 pro-
moter were responsive to Sp1 and, more importantly, that
these sites were utilized during activation following HCMV
infection. The results document a potential mechanism(s) for
the unique upregulation of the usually constitutively expressed
p65 gene product by HCMV.
The analysis of the p105/p50 promoter proved to be more
complex in SL2 cells following cotransfection of Sp1 and in
HEL fibroblasts following viral infection. The p105/p50 pro-
moter was strongly transactivated by Sp1 in a titratable fashion,
and when the documented Sp1 binding site (11) was deleted or
mutated, activity dropped under both conditions examined.
The results also demonstrated that a number of other impor-
tant factors played a critical role. When the NF-kB sites were
deleted, there was a decrease in activity, demonstrating the
functional nature of these sites in p105/p50 regulation (12, 56)
and/or an interaction between NF-kB and Sp1 (41, 46, 47, 53,
54). Nevertheless, these results, like those from the p65 pro-
moter studies, are consistent with the hypothesis that Sp1 is
involved in the regulation of both promoters during infection.
Sp1 appears to be essential for the upregulation of p65 pro-
moter activity but only one of numerous factors in the upregu-
lation of p105/p50 promoter activity. The fact that Sp1 is not
essential to the regulation of the p105/p50 promoter but rather
one of several important documented players is not surprising
and appears to arise from the complex regulation of this pro-
moter by a variety stimuli under normal conditions (11, 12, 18,
52, 56, 57). During infection, this complex regulation is further
complicated by the large number of cellular transcription fac-
tors induced during viral infection, and the induction of the
various HCMV IE genes that we have previously shown trans-
activates the NF-kB promoters (65).
In both promoters, particularly during infection, a low level
of transactivation even when upstream sites were deleted or
mutated was seen, suggesting that other factors were regulat-
ing a certain low level of activity. One possible player could be
E2F, because there exists in both of these TATA-less promot-
ers a putative E2F site which sites at the start site of transcrip-
tion (12, 56, 60). During infection, E2F message and activity
and E2F-containing complexes have been documented to in-
crease during HCMV infection (38, 43, 48, 61); thus, E2F
presents itself as a potential low-level modulating factor at
least during infection for the activation of these promoters.
Interestingly, E2F and Sp1 have recently been shown to inter-
act, and this interaction was shown to promote heightened
promoter activity (34, 39). The potential role of E2F, however,
is clouded by the fact that these promoters are not known to be
cell cycle regulated.
Presently, the mechanism for the regulation of Sp1 during
infection is unclear. Our preliminary results, however, show
that the viral IE proteins increased steady-state Sp1 mRNA
(data not shown). Unfortunately, until the Sp1 promoter is
isolated and cloned, studies about the role of the IE genes in
Sp1 promoter regulation are not possible. Our present data
demonstrate that in the presence of Sp1, the IE genes can
increase the levels of promoter transactivation, suggesting a
cooperative interaction between the viral IE products and Sp1,
at least in regard to promoter activation. These findings are
consistent with our previous study in which we showed that the
IE genes could, with a similar pattern of activity detected
(IE2-55.IE2-86.IE1-72), act as transactivators of the p65
promoter in HEL fibroblasts (65). In addition, in a recent study
showing that the HCMV IE gene products transactivate pro-
moters with upstream Sp1 sites, it was also observed that in the
absence of these upstream Sp1 activators, little activity is seen
(40), supporting our observation of little or no activity in the
absence of Sp1.
Interestingly, a recent report has documented a potential
role for pRB as a positive regulator of Sp1 by freeing func-
tional Sp1 from its negative inhibitor termed, Sp1-I (8), indi-
cating a mechanism where by Sp1 through an interaction with
another product can be relieved of its negative regulation.
Because the IE genes are expressed during the time frame in
which we saw an increase in Sp1 levels and Lukac et al. have
demonstrated an interaction between IE2-86 and Sp1 (40), the
IE products could act similarly to pRB by releasing free Sp1
from its putative negative regulator. Our results support this
hypothesis as IE2-86 increased the levels of Sp1 EMSA bind-
ing at all time points tested, suggesting a potential mechanism
by which the virus increases transcriptionally active Sp1. Al-
though pRB might be involved and is induced during infection
(30), we did not at this time address the role of this product in
the regulation of Sp1. The other IE gene products did not
significantly increase Sp1 binding, although all three interacted
with Sp1 and could cooperate with Sp1 in the CAT assays,
implying that all three of these IE gene products play some sort
of a role in the regulation of the NF-kB promoters. Because
little is known about the mechanisms of IE1-72 coactivator
function, its specific role in the regulation of Sp1 activity is
currently unknown. The same argument could be used for
IE2-55, although because of its similarity to IE2-86 and its
significant ability to cooperate with Sp1 in the CAT assays, one
might have predicted that it, like IE2-86, would have increased
Sp1 DNA binding levels. However, because IE2-55 is a splice
variant of IE2-86, it is possible that the spliced-out region
contains the active site for its ability to disrupt the Sp1 inhib-
itor, while contained in the common regions is the ability to act
as a promoter transactivator or to interact with Sp1 in a pro-
tein-protein complex. This hypothesis is consistent with the
findings that IE2-55 can antagonize IE2-86 function (4, 37, 40)
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by potentially acting as a sink for various transcription factors
(40). Thus, one might predict then that IE2-55 would bind Sp1
but not free up additional active Sp1 as the IE2-86 product
does. Nevertheless, the conflicting results as to the true role
IE2-55 plays during infection (transactivator versus negative
modulator) remain. Additional studies are under way to better
define the role that the IE genes play in Sp1-mediated regu-
lation.
Overall, our current data along with our previously reported
work clearly demonstrate that there are multiple pathways
utilized by HCMV for the regulation of the vital NF-kB activity
necessary for the maintenance and regulation of the viral life
cycle. We have shown that there are at least two tiers to the
regulation of NF-kB (65): (i) an initial induction via a receptor/
ligand-mediated signaling event in which preformed stores are
probably released (38, 62–65) and (ii) the increase in new p50
and p65 molecules through the de novo synthesis of new mes-
sage (38, 65). The increase in new NF-kB molecules itself
occurs through multiple regulated mechanisms: (i) autoregu-
lation by NF-kB (p105/p50 promoter), (ii) increase in Sp1-
directed activity (p65 and p105/p50 promoters), (iii) transacti-
vation of the cellular promoters by the viral IE proteins (p65
and p105/p50 promoters (65), and (iv) interactions between
these various players (34, 39–41, 46, 47, 53, 54).
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